BACKGROUND: Adequate calcium and vitamin D are needed to maintain calcium balance. OBJECTIVE: Our objective was to examine the influence of calcium intake and vitamin D exposure separately and their interaction on biomarkers of calcium sufficiency. DESIGN:Healthy men and women, age 20-80 yr, were randomly allocated to four groups: 1) double placebo, 2) calcium (1200 mg daily) plusplacebo, 3) vitamin D(3) (100 microg) plus placebo, and 4) vitamin D(3) and calcium. Fasting serum and urine as well as serum and urine 2 h after a calcium load (600 mg of calcium carbonate) were obtained at baseline and 3 months. RESULTS:Ninety-nine participants were randomized; 78 completed the study. Baseline demographics, protein intake and laboratory studies did not differ among the four groups. Study medication compliance was 90%. Fasting bone turnover markers declined after 3 months only in the two groups given calcium supplements and increased in the vitamin D(3) plus placebo calcium group. The calcium load resulted in a decrease in PTH and in bone turnover markers that did not differ among groups. Urinary calcium excretion increased in the combined group. Mean serum 25-hydroxyvitamin D increased from a baseline of 67 (18 sd) nmol/liter to 111 (30 sd) nmol/liter after vitamin D supplementation. CONCLUSION: Increased habitual calcium intake lowered markers of bone turnover. Acute ingestion of a calcium load lowered PTH and bone turnover markers. Additional intake of 100 microg/d vitamin D(3) did not lower PTH or markers of bone turnover.
RCT Entities:
BACKGROUND: Adequate calcium and vitamin D are needed to maintain calcium balance. OBJECTIVE: Our objective was to examine the influence of calcium intake and vitamin D exposure separately and their interaction on biomarkers of calcium sufficiency. DESIGN: Healthy men and women, age 20-80 yr, were randomly allocated to four groups: 1) double placebo, 2) calcium (1200 mg daily) plus placebo, 3) vitamin D(3) (100 microg) plus placebo, and 4) vitamin D(3) and calcium. Fasting serum and urine as well as serum and urine 2 h after a calcium load (600 mg of calcium carbonate) were obtained at baseline and 3 months. RESULTS: Ninety-nine participants were randomized; 78 completed the study. Baseline demographics, protein intake and laboratory studies did not differ among the four groups. Study medication compliance was 90%. Fasting bone turnover markers declined after 3 months only in the two groups given calcium supplements and increased in the vitamin D(3) plus placebo calcium group. The calcium load resulted in a decrease in PTH and in bone turnover markers that did not differ among groups. Urinary calcium excretion increased in the combined group. Mean serum 25-hydroxyvitamin D increased from a baseline of 67 (18 sd) nmol/liter to 111 (30 sd) nmol/liter after vitamin D supplementation. CONCLUSION: Increased habitual calcium intake lowered markers of bone turnover. Acute ingestion of a calcium load lowered PTH and bone turnover markers. Additional intake of 100 microg/d vitamin D(3) did not lower PTH or markers of bone turnover.
Authors: Karen E Hansen; Christie M Bartels; Ronald E Gangnon; Andrea N Jones; Jyothi Gogineni Journal: J Clin Rheumatol Date: 2014-03 Impact factor: 3.517
Authors: K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa Journal: Osteoporos Int Date: 2018-03-24 Impact factor: 4.507
Authors: Song Yao; Yali Zhang; Li Tang; Janise M Roh; Cecile A Laurent; Chi-Chen Hong; Theresa Hahn; Joan C Lo; Christine B Ambrosone; Lawrence H Kushi; Marilyn L Kwan Journal: Breast Cancer Res Treat Date: 2016-12-03 Impact factor: 4.872
Authors: Lisa Langsetmo; Claudie Berger; Nancy Kreiger; Christopher S Kovacs; David A Hanley; Sophie A Jamal; Susan J Whiting; Jacques Genest; Suzanne N Morin; Anthony Hodsman; Jerilynn C Prior; Brian Lentle; Millan S Patel; Jacques P Brown; Tassos Anastasiades; Tanveer Towheed; Robert G Josse; Alexandra Papaioannou; Jonathan D Adachi; William D Leslie; K Shawn Davison; David Goltzman Journal: J Clin Endocrinol Metab Date: 2013-05-23 Impact factor: 5.958